Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Kazia Therapeutics ( (KZIA) ) just unveiled an update.
On June 5, 2025, Kazia Therapeutics announced the dosing of the first patient in a Phase 1b trial of paxalisib for advanced breast cancer. This trial marks a significant expansion of paxalisib’s application beyond brain cancer, exploring its combination with olaparib or pembrolizumab. The study aims to assess the safety and efficacy of these combinations, potentially offering new therapeutic strategies for breast cancer treatment. This development is strategically important for Kazia, as it opens up new commercial opportunities and provides insights into the drug’s potential to enhance cancer treatment when combined with other therapies.
The most recent analyst rating on (KZIA) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on Kazia Therapeutics stock, see the KZIA Stock Forecast page.
Spark’s Take on KZIA Stock
According to Spark, TipRanks’ AI Analyst, KZIA is a Underperform.
Kazia Therapeutics has a low overall stock score due to significant financial instability marked by declining revenues, negative equity, and cash flow issues. Technical indicators suggest bearish momentum, and poor valuation metrics reflect the company’s unprofitability. The absence of dividends and positive earnings call or corporate events data further emphasize the company’s challenges.
To see Spark’s full report on KZIA stock, click here.
More about Kazia Therapeutics
Kazia Therapeutics Limited is an oncology-focused biotechnology company based in Sydney, Australia. The company is developing innovative therapies for difficult-to-treat cancers, with its lead program being paxalisib, an investigational inhibitor of the PI3K/Akt/mTOR pathway, primarily aimed at treating various forms of brain cancer. Kazia is also working on EVT801, a small molecule inhibitor of VEGFR3, licensed from Evotec SE.
Average Trading Volume: 43,408
Technical Sentiment Signal: Sell
Current Market Cap: $5.35M
See more data about KZIA stock on TipRanks’ Stock Analysis page.